This is a working overview of peptide content, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-25. Anything still debated is marked as such rather than presented as settled.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
== Structure == The Gβγ subunit is a dimer composed of two polypeptides, however it acts functionally as a monomer, as the individual subunits do not separate, and have not been found to function independently. The Gβ subunit is a member of the β-propeller family of proteins, which typically possess four to eight antiparallel β-sheets arranged in the shape of a propeller. Gβ contains a seven-bladed β-propeller, each blade arranged around a central axis and composed of four antiparallel β-sheets. The amino acid sequence contains seven WD repeat motifs of about 40 amino acids, each highly conserved and possessing the Trp-Asp dipeptide that gives the repeat its name. The Gγ subunit is considerably smaller than Gβ, and is unstable on its own, requiring interaction with Gβ to fold, explaining the close association of the dimer. In the Gβγ dimer, the Gγ subunit wraps around the outside of Gβ, interacting through hydrophobic associations, and exhibits no tertiary interactions with itself. The N terminus helical domains of the two subunits form a coiled coil with one another that typically extends away from the core of the dimer. To date, five β-subunit and eleven γ-subunit genes have been identified in mammals. The Gβ genes have very similar sequences, while significantly greater variation is seen in the Gγ genes, indicating that the functional specificity of the Gβγ dimer may be dependent on the type of Gγ subunit involved.
critical point The end point of a phase equilibrium curve or pressure-temperature curve at which conditions are such that phase boundaries vanish and a substance's different phases, such as liquid and vapor, can coexist. The critical point is defined by the intersection of a critical temperature, Tc, and a critical pressure, pc; above this temperature and pressure, all distinction between phases disappears and the substance becomes a supercritical fluid.
For services to the Community First Responder Scheme in North Wales. The Reverend Maureen Margaret Wilson. Member, NHS Highland Health and Social Care Chaplaincy Team. For services to Health and Wellbeing. Kenneth Winterbottom. For services to the community in Whittlesford, Cambridgeshire. Roy Wood. Coach, Aspull Wrestling Club, Wigan, Greater Manchester. For services to Wrestling and Young People. Vivienne Wood. For services to the community in the London Borough of Hammersmith and Fulham. Paula Bridget Woolven. For services to the community in East Sussex during Covid-19. Lorna Evelyn Woor. For services to the community in Cambridge. Dr Michael John Worms. For services to the community in Mill Hill, London Borough of Barnet. Louise Wright. Executive Assistant, West Midlands Lieutenancy Office. For services to Local Government and to Charity. Louise Emily Wright. For services to Business and to the community in Hereford. Ronald Wright. Fleet Technical Officer, Northumberland Fire and Rescue Service. For Public Service. Walter Clive Wrigley. For services to St Peter's NHS Healthcare Trust. Pauline Young (Pauline Holden). Lately Watch Manager, Essex County Fire and Rescue Service. For services to the community in Great Baddow, Essex. Sam David Young. For services to the community in Dunfermline.
In 1968, 31 clinicians and laboratory scientists representing 15 organizations convened to establish a formal consensus process for standardization. In 1977, CLSI was accredited by the American National Standards Institute (ANSI) as a voluntary consensus standards organization. Around the same time, CLSI became the home of the National Reference System for the Clinical Laboratory (NRSCL), a collection of reference systems intended to improve the comparability of test results, consistent with medical practice needs. CLSI is a global association with over 1,500 member organizations and individual members, along with more than 2,000 volunteers. Until 2005, CLSI was known as the National Committee for Clinical Laboratory Standards (NCCLS).
== Mechanism of action == Like morphine, pethidine exerts its analgesic effects by acting as an agonist at the μ-opioid receptor. Pethidine is often employed in the treatment of postanesthetic shivering. The pharmacologic mechanism of this antishivering effect is not fully understood, but it may involve the stimulation of κ-opioid receptors. Pethidine has structural similarities to atropine and other tropane alkaloids and may have some of their effects and side effects. In addition to these opioidergic and anticholinergic effects, it has local anesthetic activity related to its interactions with sodium ion channels. Pethidine's apparent in vitro efficacy as an antispasmodic agent is due to its local anesthetic effects. It does not have antispasmodic effects in vivo. Pethidine also has stimulant effects mediated by its inhibition of the dopamine transporter (DAT) and norepinephrine transporter (NET). Pethidine will substitute for cocaine in animals trained to discriminate cocaine from saline, probably as a result of its inhibitory actions on DAT and NET. Several analogs of pethidine such as 4-fluoropethidine have been synthesized that are potent inhibitors of the reuptake of the monoamine neurotransmitters dopamine and norepinephrine via DAT and NET. It has also been associated with cases of serotonin syndrome, suggesting some interaction with serotonergic neurons, but the relationship has not been definitively demonstrated. It is more lipid-soluble than morphine, resulting in a faster onset of action.
Sources: en.wikipedia.org
Co-developed and co-marketed with Bayer, sorafenib—sold under the trade name Nexavar—is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007. Sorafenib has also been evaluated in other types of cancer, including thyroid (as a treatment of last resort) and breast (in comparison to capecitabine). In July 2014, the company announced the phase III failure of a Sorafenib-Capecitabine combination trial. The drug combination failed to increase progression free survival of patients with advanced breast cancer.
React based in Sweden has produced informative material on AMR for the general public. Videos are being produced for the general public to generate interest and awareness. The Irish Department of Health published a National Action Plan on Antimicrobial Resistance in October 2017. The Strategy for the Control of Antimicrobial Resistance in Ireland (SARI), Iaunched in 2001 developed Guidelines for Antimicrobial Stewardship in Hospitals in Ireland in conjunction with the Health Protection Surveillance Centre, these were published in 2009. Following their publication a public information campaign 'Action on Antibiotics' was launched to highlight the need for a change in antibiotic prescribing. Despite this, antibiotic prescribing remains high with variance in adherence to guidelines. The United Kingdom published a 20-year vision for antimicrobial resistance that sets out the goal of containing and controlling AMR by 2040. The vision is supplemented by a 5-year action plan running from 2019 to 2024, building on the previous action plan (2013–2018).
=== Clinical and therapeutic evaluations === Aramwit's work has encompassed clinical and therapeutic evaluations across various health conditions. She found that mulberry leaves containing 12 mg of 1-deoxynojirimycin reduced fasting plasma glucose and glycated hemoglobin in obese individuals with borderline diabetes, with minimal side effects, and observed that their leaf powder also lowered triglyceride, LDL, and CRP levels in patients with mild dyslipidemia. In her collaborative studies, she discovered periostin as a biomarker for kidney disease severity in IgA nephropathy, demonstrated oxymetholone's muscle-enhancing effects in hemodialysis patients with liver injury risks, and detected ultrafiltration failure and fibrosis in long-term peritoneal dialysis patients through CA125 levels. Among other research works, she developed P80, a longan extract spray reducing viral adhesion, including COVID-19, as a prevention alternative, and explored crocetin's anti-cancer properties.
Failure of safety-critical polymer components can cause serious accidents, such as fire in the case of cracked and degraded polymer fuel lines. Chlorine-induced cracking of acetal resin plumbing joints and polybutylene pipes has caused many serious floods in domestic properties, especially in the US in the 1990s. Traces of chlorine in the water supply attacked polymers present in the plumbing, a problem which occurs faster if any of the parts have been poorly extruded or injection molded. Attack of the acetal joint occurred because of faulty molding, leading to cracking along the threads of the fitting where there is stress concentration.
== In degradation of drug delivery systems == Among various types of cancer, lung cancer, larynx cancer, mouth cancer, and breast cancer exhibit higher concentrations (10-40 mM) of GSH compared to healthy cells. Thus, drug delivery systems containing disulfide bonds, typically cross-linked micro-nanogels, stand out for their ability to degrade in the presence of high concentrations of glutathione (GSH). This degradation process releases the drug payload specifically into cancerous or tumorous tissue, leveraging the significant difference in redox potential between the oxidizing extracellular environment and the reducing intracellular cytosol. When internalized by endocytosis, nanogels encounter high concentrations of GSH inside the cancer cell. GSH, a potent reducing agent, donates electrons to disulfide bonds in the nanogels, initiating a thiol-disulfide exchange reaction. This reaction breaks the disulfide bonds, converting them into two thiol groups, and facilitates targeted drug release where it is needed most. This reaction is called a thiol-disulfide exchange reaction.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.